<- Go Home

Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Market Cap

EUR 16.4M

Volume

844.00

Cash and Equivalents

EUR 2.2M

EBITDA

-EUR 2.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 16.4M

Profit Margin

75.63%

52 Week High

EUR 12.18

52 Week Low

EUR 2.15

Dividend

N/A

Price / Book Value

0.92

Price / Earnings

-2.81

Price / Tangible Book Value

0.98

Enterprise Value

EUR 15.1M

Enterprise Value / EBITDA

-1.59

Operating Income

-EUR 2.8M

Return on Equity

14.71%

Return on Assets

-6.84

Cash and Short Term Investments

EUR 2.2M

Debt

EUR 927.0K

Equity

EUR 17.9M

Revenue

EUR 21.7M

Unlevered FCF

-EUR 4.3M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches